Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $100.02 USD
Change Today -0.19 / -0.19%
Volume 6.2M
JNJ On Other Exchanges
Sao Paulo
As of 8:04 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

johnson & johnson (JNJ) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/13/14 - $109.49
52 Week Low
10/15/14 - $95.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for JOHNSON & JOHNSON (JNJ)

johnson & johnson (JNJ) Details

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON’S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON’S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women’s health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, including adhesive bandages and first aid products under the BAND-AID and NEOSPORIN brand names; and nutritional products comprising no calorie sweetener under the SPLENDA brand name. This segment also offers over-the-counter medicines, including acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic, and trauma and neurological products; general surgery, and biosurgical and energy products; products to treat cardiovascular disease; infection prevention products; diagnostics products; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company distributes its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.

126,500 Employees
Last Reported Date: 02/24/15
Founded in 1885

johnson & johnson (JNJ) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: $1.5M
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $878.1K
Worldwide Chairman of Pharmaceuticals, Chief ...
Total Annual Compensation: $1.1M
Group Worldwide Chairman and Member of Execut...
Total Annual Compensation: $841.3K
Vice President, General Counsel and Member of...
Total Annual Compensation: $591.3K
Compensation as of Fiscal Year 2014.

johnson & johnson (JNJ) Key Developments

Johnson & Johnson Declares Dividend for the Third Quarter of 2015, Payable on 8 September 2015

The board of directors of Johnson & Johnson declared a dividend of USD 0.75 per share on the company's common stock for the third quarter of 2015. This cash dividend is due on 8 September 2015 to shareholders of record at the close of business as of 25 August 2015. Ex-dividend date has been set by the company board for 21 August 2015.

Johnson & Johnson Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months of 2015; Revises Earnings Guidance for the Full Year 2015

Johnson & Johnson announced unaudited consolidated earnings results for the second quarter and six months of 2015. Net earnings and diluted earnings per share for the second quarter of 2015 were $4.5 billion and $1.71, respectively against $4.326 billion and $1.78 per dilute share a year ago. Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were $4.8 billion and adjusted diluted earnings per share were $1.71, representing decreases of 6.3% and 3.9%, respectively, as compared to the same period in 2014. On an operational basis, adjusted diluted earnings per share increased 6.7%. The company announced sales of $17.8 billion for the second quarter of 2015, a decrease of 8.8% from $19.5 billion as compared to the second quarter of 2014. Earnings before provision for taxes on income was $5,741 million against $5,626 million a year ago. For the six months, net earnings were $8,836 million against $9,053 million a year ago. Earnings before provision for taxes on income was $11,316 million against $11,050 million a year ago. Net earnings per share (diluted) was $3.13 against $3.15 a year ago. Adjusted earnings before provision for taxes and net earnings was $11,878 million against $12,452 million a year ago. Adjusted earnings per diluted share was $3.27 against $3.41 a year ago. The company announced sales of $35.161 billion against $37.610 billion a year ago. The company increased its adjusted earnings guidance for full-year 2015 to $6.10 to $6.20 per share. The Company's guidance excludes the impact of after-tax intangible amortization expense and special items.

Johnson & Johnson Announces Investigational HIV Vaccine Regimen Shows Encouraging Results in Non-Human Primates

Johnson & Johnson announced that scientists at Beth Israel Deaconess Medical Center (BIDMC), Crucell Holland B.V and several other collaborators published results from a preclinical study of an HIV vaccine regimen used in non-human primates. The study, published in the online edition of Science, suggests that a "heterologous prime-boost" vaccine regimen--which first primes the immune system, then boosts the immune system to increase the response, could ultimately prove to be a strategy for protecting against global human immunodeficiency virus (HIV-1) infection. These data form the basis of vaccine regimens that are now being evaluated in an international phase 1/2a clinical trial for safety and immunogenicity in healthy, HIV-uninfected volunteers. The pre-clinical study published evaluated the protective efficacy of a "prime-boost" vaccine approach, which leverages AdVac Technology from Janssen and a trimeric envelope protein boost. Non-human primates (NHP) were first given an adenovirus serotype 26 (Ad26) vectored vaccine to prime the immune system, and then a boost of a purified HIV envelope protein intended to enhance the immune system over time. This approach is intended to increase both the magnitude of the immune response and the overall protection against subsequent viral challenge. A heterologous prime-boost vaccine regimen using a similar AdVac vector, along with an MVA-based vector, is being used in Janssen's preventative Ebola candidate vaccine regimen that is currently in Phase 1 human clinical studies.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JNJ:US $100.02 USD -0.19

JNJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $25.87 USD -0.23
Novartis AG SFr.100.90 CHF -0.20
Pfizer Inc $36.15 USD +0.09
Roche Holding AG SFr.279.60 CHF 0.00
Procter & Gamble Co/The $76.40 USD -0.30
View Industry Companies

Industry Analysis


Industry Average

Valuation JNJ Industry Range
Price/Earnings 17.6x
Price/Sales 3.9x
Price/Book 3.9x
Price/Cash Flow 17.3x
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JOHNSON & JOHNSON, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at